Define the configuration and pipeline for your new meta-analysis.
Name of the PD-1/L1 inhibitor (e.g., 'nivolumab').
Type of chemotherapy (e.g., 'platinum-based doublet').
Name of the PD-1/L1 inhibitor, if any.
Type of chemotherapy in the control arm.
Does the pairing match our criteria (e.g., IO+Chemo vs. Chemo)?
Does the trial report at least one key outcome?
Is the study a Randomized Controlled Trial?